🇺🇸 FDA
Pipeline program

turoctocog alfa

NN7008-4304

Approved small_molecule completed

Quick answer

turoctocog alfa for Congenital Bleeding Disorder is a Approved program (small_molecule) at Novo Nordisk A/S with 2 ClinicalTrials.gov record(s).

Program details

Company
Novo Nordisk A/S
Indication
Congenital Bleeding Disorder
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials